Skip to content

OTSC anastomotic clips in the endoscopic treatment of high-risk patients with acute non-variceal upper gastrointestinal bleeding: a multicentre, prospective, RCT study

OTSC anastomotic clips in the endoscopic treatment of high-risk patients with acute non-variceal upper gastrointestinal bleeding: a multicentre, prospective, RCT study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088632
Enrollment
Unknown
Registered
2024-08-22
Start date
2024-07-12
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute non-variceal upper gastrointestinal bleeding

Interventions

OTSC therapy:Clipping hemostasis was performed with endoscopic OTSC anastomosis clips
Conventional endoscopic therapy :Endoscopic injection hemostasis, thermocoagulation hemostasis, titanium clip hemostasis, etc. are used for hemostasis treatment

Sponsors

Department of Gastroenterology,Shenzhen Second People’s Hospital, Shenzhen, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Subjects voluntarily join the study and sign the informed consent; 2. Patients aged 18-80 years; 3. Able to tolerate and agree to endoscopic diagnosis and treatment; 4. Patients who meet the diagnosis of ANVUGIB high-risk patients; 5. Patients who have not received other endoscopic treatment after bleeding.

Exclusion criteria

Exclusion criteria: 1. Patients with impaired consciousness and hemorrhagic shock; 2. Patients who are unable to cooperate with or do not agree to endoscopic diagnosis and treatment; 3. Patients with serious heart, brain, and lung diseases; 4. Patients with esophageal varices or upper gastrointestinal malignant tumors; 5. Patients with abnormal or altered anatomical structures who cannot complete endoscopic diagnosis and treatment.

Design outcomes

Primary

MeasureTime frame
Immediate hemostasis rate;

Secondary

MeasureTime frame
7-day rebleeding rate;30-day rebleeding rate;Operation time;Blood transfusion volume;Length of hospital stay;Expenses of hospital stay;Incidence of adverse events;

Countries

China

Contacts

Public ContactDayong Sun

Shenzhen Second People’s Hospital, Shenzhen, China

dayongsunsz@163.com+86 136 1290 8866

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026